Additional file 2: of The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting Tesa Severson Denise Wolf Christina Yau Justine Peeters Diederik Wehkam Philip Schouten Suet-Feung Chin Ian Majewski Magali Michaut Astrid Bosma Bernard Pereira Tycho Bismeijer Lodewyk Wessels Carlos Caldas René Bernards Iris Simon Annuska Glas Sabine Linn Laura van ‘t Veer 10.6084/m9.figshare.c.3866536_D2.v1 https://springernature.figshare.com/articles/dataset/Additional_file_2_of_The_BRCA1ness_signature_is_associated_significantly_with_response_to_PARP_inhibitor_treatment_versus_control_in_the_I-SPY_2_randomized_neoadjuvant_setting/5357005 I-SPY 2 Trial participating sites and institutional review boards (IRB). (XLSX 48 kb) 2017-08-25 05:00:00 Breast cancer Neoadjuvant BRCAness PARP inhibition Triple-negative breast cancer